2024年度

Watanabe K, Yamamoto T, Fujita T, Hino S, Hino Y, Yamazaki K, Ohashi Y, Sakuraba S, Kono H, Nakao M, Ochiai K, Dan S, Saitoh N.
Metabolically inducing defects in DNA repair sensitizes BRCA –wild-type cancer cells to replication stress.
Science Signaling. 17(862), 2024.

Ochiai Y, Suzuki-Karasaki M, Ando T, Suzuki-Karasaki M, Nakayama H, Suzuki-Karasaki Y.
Nitric oxide-dependent cell death in glioblastoma and squamous cell carcinoma via prodeath mitochondrial clustering.
Eur J Cell Biol. 103(2):151422, 2024.

Toya R, Fukugawa Y, Saito T, Matsuyama T, Yoshida R, Murakami D, Orita Y, Nakayama H, Oya N.
Radiation Therapy Oncology Group 8502 "QUAD shot" regimen using volumetric modulated arc therapy for incurable head and neck cancer.
Oral Oncol. Mar 21:151:106752, 2024.

Ishikawa K, Matsuoka Y, Shinohara K, Inoue J, Yano H, Eto T, Yamamoto T, Yamana K, Gohara S, Takeshita H, Hirayama M, Kawahara K, Hirosue A, Fukugawa Y, Yoshida R, Komohara Y, Nakayama H.
Involvement of ferroptosis-defensive xCT/GPX4 axis in radioresistance and its impacts on prognosis in oral squamous cell carcinoma.
Oral Sci Int. 21(3):359-372, 2024.

Seki Y, Yamana K, Yoshida R, Inoue J, Shinohara K, Oyama T, Kubo R, Nagata M, Kawahara K, Hirayama M, Takahashi N, Nakamoto M, Hirosue A, Kariya R, Okada S, Nakayama H.
Programmed death-ligand 1-expressing extracellular vesicles are a prognostic factor in patients with oral squamous cell carcinoma treated with immune checkpoint inhibitors.
Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology. 36(4):518-525, 2024.

Yamakawa N, Harada H, Nakayama H, Ohiro Y, Bukawa H, Kirita T.
Preoperative chemoradiotherapy for locally advanced oral squamous cell carcinoma: A multicenter retrospective study.
Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology.36(1):11-20, 2024.

Morodomi S, Hirosue A, Rahman A, Nohata K, Matsuo M, Reda O, Alam Rajib S, Saito H, Takeda H, Yoshida R, Nakamoto M, Hirayama M, Kawahara K, Takatori M, Orita Y, Nakayama H, Satou Y.
Robust HPV-16 Detection Workflow for Formalin-Fixed Cancer Tissue and Its Application for Oral Squamous Cell Carcinoma.
Cancer Med. 14(4):e70544, 2025.

Ooyama T, Hirayama M, Seki Y, Iwamoto A, Yoshida R, Nakayama H.
Pretreatment nutritional indices are associated with survival and T-cell exhaustion in recurrent or metastatic oral squamous cell carcinoma patients treated with immune checkpoint inhibitors: a retrospective cohort study.
nternational Journal of Oral and Maxillofacial Surgery. In press, 2025.

Kubo R, Yoshida R, Baba-Tajiri R, Nakamura-Yamada H, Miyahara T, Ooyama T, Inoue J, Hirosue A, Kawahara K, Nakamoto M, Hirayama M, Miyamoto T, Nakayama H.
Differences in alveolar bone mineral density by tooth type in female osteoporotic patients treated with bisphosphonates.
Oral Science International. 22(1), 2025.

Inoue J, Yamana K, Hirosue A, Kawahara K, Yoshida R, Seki Y, Nakamoto M, Shinohara K, Hirayama M, Takahashi N, Nakayama H.
Exosome-derived miR-1290 in blood as a predictive biomarker for occult neck metastasis in patients with cT1-2N0 tongue cancer.
Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology. Available online 4 January 2025.

Yoshida T, Takashima K, Yohana S Mtali, Miyashita Y, Iwamoto A, Fukushima Y, Nakamura K, Oshiumi H.
Regulation of IL-17A-mediated hypersensitivity by extracellular vesicles and lipid nanoparticles carrying miR-451a.
Journal of Immunology. In press, 2025.